Loading…
← CockpitCompetitor Analysis › 000538.SZ Yunnan Baiyao Group Co. Ltd. Class AOpen in the cockpit ↗

Yunnan Baiyao Group Co. Ltd. Class A000538.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Well-known Chinese-medicine brand maker, selling wound-care products, toothpaste and traditional medicines nationwide.

≈ A Chinese Johnson & Johnson consumer-health/traditional-medicine hybridMomentum leader 96
Mkt cap
$15.0B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$84.3M
20-day average traded
Fwd P/E
18.3×
forward earnings
ROIC−WACC
+8.3 pp
WACC 5.0%
Hurdle
-5 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥56.27
1D0.0%
1W+3.6%
1M+5.4%
3M+11.5%
6M+10.6%
YTD-0.9%
1Y+0.6%
ATR %1.7%
52w lowhigh3.3% off high

What Yunnan Baiyao does

Well-known Chinese-medicine brand maker, selling wound-care products, toothpaste and traditional medicines nationwide.

A large share of reported revenue comes from reselling other firms' medicines, which earns thin margins, while branded Yunnan Baiyao products supply most of the profit. They are sold through pharmacies and supermarkets, online stores and hospitals.

In one line: A Chinese Johnson & Johnson consumer-health/traditional-medicine hybrid.

Products and services

  • Wound-care/hemostatic products
  • Toothpaste & oral care
  • Traditional Chinese medicines
  • Pharmaceutical distribution

Customers

  • Chinese retail consumers
  • pharmacies and hospitals

Where it sits in the supply chain

  • Health care/Consumer
  • Traditional Chinese medicine & consumer…
  • Wound-care products, toothpaste, TCM…

What could go right

  • Brand-driven consumer-health demand
  • Toothpaste/oral-care market-share gains

What could go wrong

  • Raw-material (herbal) cost/supply risk
  • Distribution-business margin dilution

Moat: wide (brand, IP / patents). Century-old secret-formula brand with strong consumer trust across wound-care and oral-care categories.

Headquarters: Kunming, Yunnan, China · Founded: 1971 · Employees: 9,286

Named competitors

Yunnan Baiyao at a glance

Size Yunnan Baiyao (000538.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $15.0B, the 145th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥56.27 on 18 Nov 2026.

Performance Over six months the shares gained 10.6%, against +4.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 5.2% over the last twelve months (peer median +18.9%); the operating margin is 11.4% (peer median 23.1%).

Valuation It trades at 18.3× forward earnings against a peer median of 28.0× (7th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026000538.SZ 111Peer median 105
Six months, rebased to 100: Yunnan Baiyao against the median of its 20 peers (local-currency closes).

Yunnan Baiyao financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥42.8BCN¥41.0BCN¥39.9BCN¥38.9BCN¥36.3B
Revenue growth—+3%+2%+7%—
Gross profitCN¥12.5BCN¥11.8BCN¥10.9BCN¥9.94BCN¥9.15B
EBITDAn/aCN¥5.15BCN¥4.92BCN¥3.99BCN¥3.75B
Net incomeCN¥5.20BCN¥5.15BCN¥4.75BCN¥4.09BCN¥3.00B
Free cash flowCN¥5.00BCN¥4.44BCN¥4.04BCN¥3.36BCN¥3.33B
Capital expenditureCN¥534MCN¥480MCN¥675MCN¥576MCN¥447M
Total debtCN¥2.05BCN¥2.33BCN¥2.62BCN¥3.85BCN¥4.29B

Quarterly statements and history in the cockpit →

Yunnan Baiyao competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%6885066446IPNORNAVJAZZSOBILAURUSLABSEXELASND6990ZYDUSLIFEDRREDDY1177RECTORNTPHARM1801600436ALNY000538.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Yunnan Baiyao is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×6446IPNORNAVJAZZLAURUSLABSASND69904507DRREDDY1801600436ALNY000538.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Yunnan Baiyao is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%6446IPNORNAVLAURUSLABSASND69904507DRREDDYTORNTPHARM1801600436ALNY000538.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Yunnan Baiyao is the large dot.

Yunnan Baiyao competitors and peer comparison

Head to head with its named competitors (000538.SZ vs 1666.HK vs CL vs PG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Tong Ren Tang Technologies 1666.HK$491M-19%-14%12%7.3×-17.2%
Colgate-Palmolive CL$78.6B+9%+6%22%24.7×-4.9%
Procter & Gamble PG$395B+20%+4%24%24.1×0.5%

How Yunnan Baiyao compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Yunnan Baiyao against its 20 peers (data as of 18 Nov 2026)
Measure000538.SZPeer medianRank in peer set
1-month return+5.4%+6.1%10th lowest of 21
6-month return+10.6%+4.4%7th highest of 21
Distance from 52-week high-3.3%-7.2%5th highest of 21
Revenue growth (TTM)+5.2%+18.9%3rd lowest of 21
Operating margin11.4%23.1%4th lowest of 21
Forward P/E18.3×28.0×7th cheapest of 20
Growth the price implies (Req g, 7 yrs)-0.2%6.4%7th least demanding of 19
Growth delivered (Del g)+4.7%+12.6%lowest of 19
Hurdle (Req g minus delivered)-4.9 pp-12.7 pp7th most demanding of 19
ROIC minus cost of capital+8.3 pp+7.2 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%

Questions

Who are Yunnan Baiyao's main competitors?
Named competitors: Tong Ren Tang Technologies (1666.HK), Colgate-Palmolive (CL), Procter & Gamble (PG). The cockpit's measured peer set (industry) also includes Sichuan Biokin Pharmaceutical (688506.SS), PharmaEssentia (6446.TW), Ipsen (IPN.PA), Orion (ORNAV.HE), Jazz Pharmaceuticals Public (JAZZ), Swedish Orphan Biovitrum (SOBI.ST).
Is Yunnan Baiyao expensive compared with its peers?
On forward p/e it trades at 18.3× against a peer median of 28.0×, 7th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Yunnan Baiyao stock performed?
Over six months to 18 Nov 2026 the shares returned +10.6% against +4.4% for the median peer; over one year +0.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.